USFDA revokes approval for Ranbaxy’s capsules

January 27, 2015 07:34 pm | Updated 07:34 pm IST - MUMBAI:

In more trouble for Ranbaxy Laboratories, the U.S. Food and Drug Administration (FDA) has revoked the Indian company’s 180-day exclusivity to market esomeprazole magnesium delayed release capsule 20 mg and 40 mg in the U.S.

Instead, the regulator has allowed Ivax Pharmaceuticals, Inc., a subsidiary of Teva Pharmaceuticals USA, to market esomeprazole in 20 and 40 mg capsules in the U.S. market.

On Monday, it had approved the first generic version of Nexium (esomeprazole magnesium delayed-release capsules) to treat gastroesophageal reflux disease (GERD) in adults and children. Esomeprazole is a proton pump inhibitor that reduces the amount of acid in the stomach.

Esomeprazole is used for treatment of stomach and esophagus problems.

Ranbaxy said it would take legal recourse to challenge US FDA’s decision to revoke the approval.

“On November 4, 2014, we received a notice from the US FDA rescinding our tentative approvals for esomeprazole magnesium delayed release capsule 20 mg and 40 mg and for valganciclovir hydrochloride tablets USP, 450 mg,” Ranbaxy said in a filing to the stock exchange.

“We have now received a communication from US FDA that they have determined that Ranbaxy has forfeited its 180-day exclusivity for esomeprazole magnesium delayed release capsule 20 mg and 40 mg. Ranbaxy is disappointed with the result, and is pursuing all available legal options to preserve its rights,” it added.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.